CClinicalTrials.gg
RecruitingNCT04134754Updated Jun 23, 2026

Carbon Dioxide (CO2) Chemosensitivity and SUDEP

An interventional study of 6% Carbon dioxide/50% oxygen/balance nitrogen mixture in Epilepsy and SUDEP, sponsored by University of Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by University of Iowa · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
335
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The purpose of this research study is to better understand what causes Sudden Unexpected Death in Epilepsy (SUDEP). This study will enroll subjects from the University of Iowa Hospitals and Clinics (UIHC) Epilepsy Monitoring Unit (EMU) and Epilepsy Clinics. The investigators will analyze the effects of seizures on breathing, on the cardiovascular system, and on arousal. The investigators are studying these effects because some cases of SUDEP might be due, in part, to an inability to wake up or sense elevated carbon dioxide (CO2) levels when breathing is impaired. Subjects will be followed for ten years after enrollment to monitor their health.

Read the detailed description

In this study, the investigators will only enroll adults with confirmed or suspected epilepsy; there is no control group. Patients admitted to the UIHC Epilepsy Monitoring Unit (EMU) for continuous VideoEEG will undergo video recordings of their face and body, electroencephalography (EEG), and electrocardiogram (ECG) as part of their normal clinical care. Research subjects will undergo noninvasive cardiorespiratory monitoring during their EMU stay for the purpose of correlating heart rate and breathing patterns with EEG patterns related to their seizures.

Eligible subjects will undergo several respiratory tests. This may include sniffing and breath holding and breathing through tubes of different sizes. One test, called the hypercapnic ventilatory response (HCVR), will have you rebreathe a gas mixture of 6% carbon dioxide and 50% oxygen to look at how more you breath in response to the increase in carbon dioxide levels. The investigators will then measure how much more subjects breathe in response to the increase in carbon dioxide levels, and also how breathing feels at the end of the test. The investigators will analyze the relationship between the HCVR and cardiorespiratory changes from seizures. The investigators will also analyze the effect of seizures on the HCVR. The HCVR test will be done by our respiratory therapist during subjects' stay in the EMU.

Some subjects will be asked to participate in repeat testing of the HCVR 3 more times as an outpatient over the next 2 years. Additional subjects will also be enrolled from the clinic and will also undergo HCVR testing 4 times over the 2 years. All subjects will agree to undergo an interview in person or by phone, email, or questionnaire annually for ten years. They will also provide consent for follow-up with a personal contact in the event of subject death, for the purpose of ascertaining whether the death was due to SUDEP.

02

Conditions studied

  • Epilepsy
  • SUDEP

Browse trials for

Keywords

  • Epilepsy
03

In context

Epilepsy

1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.

This study's planned enrollment of 335 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

University of Iowa is the lead sponsor of 276 studies on the registry; 35 are open to participants now.

Of its 44 completed or terminated interventional studies of FDA-regulated products, 39 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. The subject is between 18 and 99 years of age.
  2. Confirmed or suspected epilepsy.
  3. Admission to the EMU for spell characterization (EMU group) or undergoing care in the University of Iowa Health Care Epilepsy Clinic.

Exclusion criteria

Exclusion Criteria:

  1. History of uncontrolled cardiac, pulmonary, or hepatic disease.
  2. Progressive or uncontrolled neurologic disease unrelated to epilepsy.
  3. Current opioid use.
  4. Women of child-bearing potential who are pregnant or capable of becoming pregnant (e.g. sexual activity within the past 21 days without a highly effective form of birth control or positive urine pregnancy test).
  5. Other comorbid condition that may influence the safety or feasibility of HCVR testing.
  6. Limited decision-making capacity and absence of a qualified representative.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
335 participants (estimated)

Study arms

  • Other
    Respiratory physiology testing

    Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.

    Other: 6% Carbon dioxide/50% oxygen/balance nitrogen mixture

Interventions

  • Other6% Carbon dioxide/50% oxygen/balance nitrogen mixture

    In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you

06

What researchers measure

Primary outcomes

  1. Determine the correlation between baseline central CO2 chemosensitivity and the increase in transcutaneous CO2 levels after a seizure.

    The change in HCVR slope (change in minute ventilation \[liters/min\] vs change in end tidal CO2 \[mm Hg\]) will be correlated with the increase in transcutaneous CO2 level (mm Hg) provoked by a seizure.

    Time frame: Immediately before and after a seizure, variable for each subject but approximately 10 minutes

  2. Determine the correlation between baseline central CO2 chemosensitivity and the duration of transcutaneous CO2 elevation above baseline after a seizure.

    The change in HCVR slope (change in minute ventilation \[liters/min\] vs change in end tidal CO2 \[mm Hg\]) will be correlated with the duration (minutes) of end tidal CO2 elevation above pre-seizure baseline

    Time frame: Duration of hospital admission, approximately 5 days

  3. Effect of seizures on HCVR slope (liters/min/mm Hg)

    The percent change in HCVR slope (liters/min/mm Hg) from baseline that is induced by a seizure will be measured. The HCVR will be administered at 30 minutes, 2 hours, and 18 hours after nonconvulsive seizures. The HCVR will be administered at 2 hours and 18 hours after convulsive seizures.

    Time frame: Up to 18 hours after a seizure.

  4. Determine the stability of the HCVR slope over time in patients with epilepsy. of the HCVR over time in patients with epilepsy

    The stability of the HCVR slope (liters/min/mm Hg) measured 8 months for 2 years will be assessed using a generalized linear mixed model.

    Time frame: 2 years

Secondary outcomes

  1. Change in respiratory rate provoked by seizures

    Frequency of breaths (breaths/minute) will be measured using respiratory effort belts around the chest and abdomen

    Time frame: Immediately before and after a seizure, variable for each subject but approximately 10 minutes

07

Study locations

1 of 1 sites recruiting
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
    • Deidre Dragon, BS · Contact · dragond@uiowa.edu · (319) 356-4337
    • Brian K Gehlbach, MD · Contact · brian-gehlbach@uiowa.edu · 319-356-3603
    • Brian Gehlbach, MD · Principal investigator
    • George Richerson, MD, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study data will be shared upon with qualified investigators upon completion of the study, under the guidelines of the NIH Data Sharing Policy and Implementation Guidance and under the control of the Principal Investigators.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04134754
Lead sponsor
University of Iowa
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Responsible party
Brian Gehlbach (MD, University of Iowa) — Principal investigator
First posted
Oct 22, 2019
Start date
Dec 12, 2019
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Jun 23, 2026

Study contacts

Study Coordinator
Contact
dragond@healthcare.uiowa.edu
319-356-4337
Brian Gehlbach, MD
principal investigator · University of Iowa
George Richerson, MD, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion